Skip to main content
XERS
NASDAQ Life Sciences

Recorlev strength drives 29% revenue jump for Xeris in Q2, but debt extinguishment loss sinks bottom line

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$7.332
Mkt Cap
$1.271B
52W Low
$5.25
52W High
$10.08
52W Position info
40% above low
Off High info
27% below high
Rel. Volume info
1.9× avg
Market data snapshot near publication time

XERS sits 40% above its 52-week low of $5.25 on elevated volume (1.9× avg).

Summary

Xeris Biopharma reported Q2 2026 revenue of $92.1 million, a 29% increase driven by Recorlev, but a non-cash debt extinguishment loss of $30.8 million resulted in a net loss of $31.1 million. The company retired all remaining convertible notes in July, strengthening the balance sheet.


Key Events · Earnings and Guidance · XERS

  • Recorlev Revenue Surges 81%

    Recorlev net revenue reached $56.8 million in Q2 2026, an 80.6% increase year-over-year, driven by higher patient demand and favorable pricing.

  • Non-Cash Debt Extinguishment Loss

    A $30.8 million non-cash loss was recognized from an exchange agreement on 2028 convertible notes, representing the difference between amortized cost and fair value.

  • Positive Operating Cash Flow

    Net cash provided by operating activities was $18.1 million for the first half of 2026, a significant improvement from a $9.8 million use of cash in the prior year period.

  • Convertible Notes Fully Retired

    In July 2026, the company settled all remaining 2028 convertible notes, issuing 8.6 million shares and paying $23.0 million in cash, eliminating $33.6 million in debt.


Analysis · XERS · Life Sciences

Strong top-line growth was fueled by Recorlev revenue nearly doubling year-over-year, yet a $30.8 million non-cash loss from retiring convertible notes pushed the bottom line deep into the red. The company generated positive operating cash flow and ended the quarter with $121.7 million in cash, providing ample runway. The subsequent elimination of all remaining 2028 convertible notes removes a significant overhang, though the chief legal officer's newly adopted 10b5-1 plan to sell up to 300,000 shares warrants attention.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, XERS was trading at $7.33 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $5.25 to $10.08. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

XERS - Latest Insights

XERS
Nov 05, 2026, 4:08 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $12.67
Real-time Price: $16.67 info
Change: +$4.00 (+32%) info
Market Cap: $3.044B info
XERS
Nov 05, 2026, 2:22 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $13.17
Real-time Price: $16.67 info
Change: +$3.51 (+27%) info
Market Cap: $3.044B info
XERS
Nov 05, 2026, 7:12 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $11.48
Real-time Price: $16.67 info
Change: +$5.19 (+45%) info
Market Cap: $3.044B info
XERS
Nov 05, 2026, 7:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $10.75
Real-time Price: $16.67 info
Change: +$5.92 (+55%) info
Market Cap: $3.044B info
XERS
Nov 05, 2026, 7:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $10.48
Real-time Price: $16.67 info
Change: +$6.19 (+59%) info
Market Cap: $3.044B info